Aardvark Therapeutics, Inc. (NASDAQ:AARD) Stock Has Average Price Target of $11.56

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have been given a consensus rating of “Hold” by the nine analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $11.56.

A number of equities research analysts have issued reports on the stock. BTIG Research dropped coverage on shares of Aardvark Therapeutics in a research report on Monday, October 12th. They issued a “neutral” rating for the company. Raymond James Financial reiterated a “market perform” rating on shares of Aardvark Therapeutics in a report on Friday. HC Wainwright reduced their price objective on Aardvark Therapeutics from $4.00 to $2.00 and set a “hold” rating for the company in a research report on Monday, October 26th. Royal Bank Of Canada set a $2.50 target price on Aardvark Therapeutics in a research note on Friday, October 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Tuesday, September 29th.

Insider Buying and Selling at Aardvark Therapeutics

In related news, insider Nelson Sun sold 62,000 shares of Aardvark Therapeutics stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00. Following the sale, the insider directly owned 35,475 shares of the company’s stock, valued at $183,760.50. This trade represents a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 17.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its position in Aardvark Therapeutics by 30.8% in the 1st quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock worth $111,000 after purchasing an additional 6,905 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Aardvark Therapeutics in the 3rd quarter valued at $124,000. Susquehanna International Group LLP acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter valued at $138,000. Ieq Capital LLC bought a new stake in shares of Aardvark Therapeutics during the second quarter worth $221,000. Finally, J. Goldman & Co LP acquired a new position in shares of Aardvark Therapeutics during the second quarter valued at $233,000.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ AARD traded down $0.19 during trading on Thursday, reaching $1.33. The stock had a trading volume of 402,447 shares, compared to its average volume of 1,698,199. Aardvark Therapeutics has a one year low of $0.93 and a one year high of $16.60. The stock has a market cap of $29.10 million, a PE ratio of -0.41 and a beta of 4.38. The firm’s 50 day moving average price is $3.76 and its two-hundred day moving average price is $5.72.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.19). On average, research analysts expect that Aardvark Therapeutics will post -3.05 earnings per share for the current year.

About Aardvark Therapeutics

Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.